Please use this identifier to cite or link to this item:
|Title:||Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.||Austin Authors:||Nicholaou, Theo;Ebert, Lisa;Davis, Ian D;Robson, Neil;Klein, Oliver ;Maraskovsky, Eugene;Chen, Weisan;Cebon, Jonathan S||Affiliation:||Ludwig Institute for Cancer Research, Cancer Vaccine Programme, Austin Hospital, Victoria, Australia||Issue Date:||1-Jun-2006||Publication information:||Immunology and Cell Biology; 84(3): 303-17||Abstract:||Since the early 1990s, numerous cancer Ag have been defined and for a handful of these there is now some clinical experience, which has made it possible to assess their value as targets for cancer immunotherapy. The cancer-testis Ag have been particularly attractive because their expression is limited to cancer and virtually no non-malignant cells apart from germ cells and trophoblast. Among these, NY-ESO-1 has been the focus of our attention. The exceptional immunogenicity of this Ag coupled with its widespread distribution among many cancer types make it a very good vaccine candidate, with the potential to be used in vaccines against many types of malignancies. This article reviews emerging knowledge about the biology of NY-ESO-1 and experience with the early clinical development of vaccines directed against NY-ESO-1. These early studies have yielded a wealth of information about the immunology of NY-ESO-1 and set the scene for future clinical strategies for immune targeting of cancer.||Gov't Doc #:||16681828||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10151||DOI:||10.1111/j.1440-1711.2006.01446.x||URL:||https://pubmed.ncbi.nlm.nih.gov/16681828||Type:||Journal Article||Subjects:||Antigens, Neoplasm.immunology
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 2, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.